Osteoporosis
Conditions
Brief summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Detailed description
This is a non-randomized, non-interventional study that is part of the RCT DUPLICATE initiative (www.rctduplicate.org) of the Brigham and Women's Hospital, Harvard Medical School. It is intended to replicate, as closely as is possible in healthcare insurance claims data, the trial listed below/above. Although many features of the trial cannot be directly replicated in healthcare claims, key design features, including outcomes, exposures, and inclusion/exclusion criteria, were selected to proxy those features from the trial. Randomization is also not replicable in healthcare claims data but was proxied through a statistical balancing of measured covariates according to standard practice. Investigators assume that the RCT provides the reference standard treatment effect estimate and that failure to replicate RCT findings is indicative of the inadequacy of the healthcare claims data for replication for a range of possible reasons and does not provide information on the validity of the original RCT finding.
Interventions
DRUGRaloxifene
Raloxifene dispensing claim is used as the reference group.
DRUGZoledronic Acid
Zoledronic Acid dispensing claim is used as the exposure group.
Sponsors
Brigham and Women's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Criteria: Please see https://drive.google.com/drive/folders/1WD618wrywYjEaXzfLTcuK-VCcnb6b-gV for full code and algorithm definitions. Eligible cohort entry dates: Zoledronic acid indication for treatment of postmenopausal women with osteoporosis was approved by FDA on Aug 20, 2007. * For IBM MarketScan: Aug 21, 2007 - December 31, 2018 (end of available data) * For Optum CDM: Aug 21, 2007 - Mar 31, 2020 (end of available data) Inclusion Criteria: * Postmenopausal women between the ages of 65 and 89 years * Osteoporosis diagnosis
Exclusion criteria
* Bisphosphonate users * Previous use of: 1. Any use of parathyroid hormone 2. Use of anabolic steroids or growth hormone within 6 months before cohort entry date OR 3. Use of oral or intravenous systemic corticosteroids within 12 months of cohort entry date * Serious disease that may limit life expectancy to less than 6 months * Malignant neoplasm diagnosis within 12 months prior to the cohort entry date * Conditions that influence bone metabolism * Treatment and Prevention of Glucocorticoid-Induced Osteoporosis * Treatment of Paget's Disease of Bone * Alcohol abuse/dependence OR Drug abuse/dependence OR Non-compliance * Pregnancy * Diagnosis and procedure for amputee of lower limb * Use of Zoledronic acid within 450 days prior to the cohort entry date * Use of Denosumab within 450 days prior to the cohort entry date * Diagnosis of End-Stage Renal Disease OR Diagnosis and procedure for Kidney transplant * Diagnosis of End-Stage Liver Disease: Cirrhosis, Hepatic decompensation * Blindness or compromised vision * Use of Abaloparatide within 450 days prior to the cohort entry date * Use of Romosozumab within 450 days prior to the cohort entry date
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with hip fracture | Through study completion (earliest of 540 days or censoring) | Please refer to attached protocol for full definition due to size limitations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with non-vertebral fracture | Through study completion (earliest of 540 days or censoring) | Please refer to attached protocol for full definition due to size limitations |
Countries
United States
Outcome results
None listed